Oxaliplatin-induced peripheral neuropathy and neuropathic pain: mechanisms involved and possible therapeutic strategies

C.A MIGUEL; M.C RAGGIO; S.L GONZALEZ; M.F CORONEL

Córdoba

Congreso; XXXIII Reunion Anual de la Sociedad Argentina de Investigacion en Neurociencias; 2018

Sociedad Argentina de Investigación en Neurociencias

Chemotherapy-induced peripheral neuropathy is a common and debilitating side effect of cancer therapy. Symptoms are predominantly sensory with the development of chronic neuropathic pain. No available strategies can limit the neuropathy. Here, we evaluated the use of 17-hydroxyprogesterone caproate (HPGC) as a neuroprotective agent and studied glial activation as a possible contributor to neuropathy. Male rats were injected with oxaliplatin (OXA) and HPGC following prophylactic (HPGCp) or therapeutic (HPGCt) schemes (starting either before or after chemotherapy). The development of hypersensitivity and allodynic pain and the expression of glial and pro-inflammatory markers were evaluated. Animals receiving OXA showed a decrease in paw mechanical and thermal thresholds (p0.05), while those treated with HPGCt showed a reversion of both hypersensitivities after HPGC administration (p>0.05 vs CTL). A significant increase in the mRNA levels of GFAP, Iba1, TNF and Il1 was detected in the dorsal root ganglia and dorsal horn of OXA animals (p